- Trials with a EudraCT protocol (242)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
242 result(s) found for: Chronic respiratory failure.
Displaying page 5 of 13.
EudraCT Number: 2017-002217-59 | Sponsor Protocol Number: 63623872FLZ3002 | Start Date*: 2018-05-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, ... | |||||||||||||
Medical condition: Influenza A Infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) EE (Completed) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) BE (Completed) BG (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003250-16 | Sponsor Protocol Number: MTI-110 | Start Date*: 2017-12-11 | |||||||||||
Sponsor Name:Menlo Therapeutics Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Refractory Chronic Cough | |||||||||||||
Medical condition: Refractory Chronic Cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000739-28 | Sponsor Protocol Number: AIFA-ICSLIFE-001 | Start Date*: 2018-06-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA | |||||||||||||
Full Title: Comparison of 1-year treatment with inhaled long acting bronchodilators (LABD) plus inhaled glucocorticosteroids (ICS) versus LABD without ICS on re-hospitalizations and/or death in elderly patient... | |||||||||||||
Medical condition: chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002484-60 | Sponsor Protocol Number: 2020-002484-6060 | Start Date*: 2021-07-12 | |||||||||||||||||||||
Sponsor Name:Odense Universityhospital | |||||||||||||||||||||||
Full Title: Intrapleural Fibrinolysis and DNase versus VATS for the treatment of pleural empyema: a randomized, controlled trial. | |||||||||||||||||||||||
Medical condition: Pleural Empyema | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000253-21 | Sponsor Protocol Number: CLA-CC10-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Therabron Therapeutics Inc. | |||||||||||||
Full Title: Efficacy of recombinant human club (clara) cell 10kDa protein (CC10) administered to premature neonates with respiratory distress syndrome. | |||||||||||||
Medical condition: Bronchopulmonary Dysplasia (BPD) | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022796-62 | Sponsor Protocol Number: MAB115032 | Start Date*: 2010-11-04 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD. | ||
Medical condition: Chronic Obstructive Pulmonary Disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) SE (Completed) SK (Completed) DE (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001719-21 | Sponsor Protocol Number: 1237-0095 | Start Date*: 2019-12-23 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A randomized, double blind, placebo-controlled, multi-center, parallel group study to compare the efficacy of inhaled tiotropium + olodaterol, fixed dose combination (5μg/5μg) vs. placebo delivered... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001265-36 | Sponsor Protocol Number: UCDCRC/20/01 | Start Date*: 2020-05-05 | |||||||||||
Sponsor Name:University College Dublin | |||||||||||||
Full Title: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the ... | |||||||||||||
Medical condition: SARS-CoV-2 PCR-positive population | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002029-28 | Sponsor Protocol Number: RC20_0191 | Start Date*: 2021-02-05 | |||||||||||
Sponsor Name:CHU Nantes | |||||||||||||
Full Title: Doxycycline Versus Placebo in COVID-19 + Patients without hospitalization criteria: Prospective, multicenter, randomized, double-blind, prospective study. | |||||||||||||
Medical condition: COVID-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000967-10 | Sponsor Protocol Number: RC31/14/7441 | Start Date*: 2019-05-24 |
Sponsor Name:University Hospital Toulouse | ||
Full Title: Autologous transplantation of Adipose tissue derived mesenchymal Stroma/stem Cells (ASC) in patients with critical limb ischemia: a phase II study (ACellDream 2). | ||
Medical condition: Patients with rest pain or ischemic ulcers/gangrene of the lower limb and without option for revascularization or poor option. Or patients with with rest pain or ischemic ulcers and persistent CL... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001730-17 | Sponsor Protocol Number: BAP00248/307 | Start Date*: 2004-09-16 | |||||||||||
Sponsor Name:Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |||||||||||||
Full Title: A Phase 3, Randomized Double-Blind Study of Ceftobiprole Medocaril Versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia | |||||||||||||
Medical condition: Nosocomial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) HU (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000623-13 | Sponsor Protocol Number: VIR-7831-5008 | Start Date*: 2021-07-29 | ||||||||||||||||
Sponsor Name:Vir Biotechnology, Inc. | ||||||||||||||||||
Full Title: A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the... | ||||||||||||||||||
Medical condition: Mild/moderate COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) AT (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003268-25 | Sponsor Protocol Number: AT-03A-017 | Start Date*: 2023-05-12 | |||||||||||
Sponsor Name:Atea Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001240-61 | Sponsor Protocol Number: allo-APZ2-ACLF-II-01 | Start Date*: 2018-12-19 | |||||||||||
Sponsor Name:RHEACELL GmbH & Co. KG | |||||||||||||
Full Title: An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF) | |||||||||||||
Medical condition: Acute-on-Chronic Liver Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014377-40 | Sponsor Protocol Number: Bay 58-2667/14560 | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004154-22 | Sponsor Protocol Number: TR701-132 | Start Date*: 2014-04-17 | |||||||||||
Sponsor Name:Trius Therapeutics, a Wholly Owned Subsidiary of Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Double-blind Study Comparing TR 701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia | |||||||||||||
Medical condition: Ventilated Gram-positive nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) GR (Completed) SK (Completed) CZ (Completed) EE (Completed) GB (Completed) HR (Completed) PT (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004427-20 | Sponsor Protocol Number: CHHEF | Start Date*: 2020-02-07 | |||||||||||
Sponsor Name:Luis Puente Maestu | |||||||||||||
Full Title: PHASE IV, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, CROSSOVER, PLACEBO-CONTROLLED STUDY, TO INVESTIGATE THE EFFECT OF DUAL BRONCHODILATION WITH UMECLIDINIUM VILANTEROL ON PATIENTS WITH COPD, HYPERIN... | |||||||||||||
Medical condition: Chronic obstructive pulmonary diseases with Heart Failure with eyection ventricular ejection fraction between 35-50% | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000398-11 | Sponsor Protocol Number: GS-US-205-0170 | Start Date*: 2015-02-03 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for t... | |||||||||||||
Medical condition: Cystic fibrosis and chronic infection of lower respiratory tract with Pseudomonas aeruginosa | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002512-40 | Sponsor Protocol Number: 201023 | Start Date*: 2016-12-05 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospit... | |||||||||||||
Medical condition: Hospitalized influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Completed) NL (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000769-13 | Sponsor Protocol Number: AP SEP 02-02 | Start Date*: 2006-06-13 |
Sponsor Name:AM-Pharma | ||
Full Title: A double-blind, randomized, placebo-controlled study to investigate the clinical efficacy and safety of two doses of Alkaline Phosphatase administered for three days in patients with severe sepsi... | ||
Medical condition: Severe sepsis and septic shock | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
